Qomolangma Acquisition Corp. Unit (QOMOU) Peer Comparison
$11.31
$0.00 (0.00%)As on 11-Feb-2026 09:30EDT
Market cap
$-- Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Edit
| Qomolangma Acquisition Corp. Unit (QOMOU) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
-- | 5,305 | 3,348 | 778 | 451 |
Revenue ($ Mln) |
-- | 440 | 2,883 | -- | 330 |
Net Profit ($ Mln) |
-0.14 | -1,435.01 | -118.30 | -134.20 | 100.20 |
Net Margin (%) |
-- | -325.91 | -4.10 | -- | 30.33 |
RoE (%) |
-3.20 | -- | -- | -40.17 | 30.44 |
Price to Earnings |
-- | -- | -- | -- | 4.72 |
Price-To-Book |
-- | -- | 1.35 | -- | 1.32 |
Income Statement ($ Mln)
| Qomolangma Acquisition Corp. Unit (QOMOU) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
-- | 510.67 | 3,195.50 | -- | 296.66 |
|
Cost of Revenue
|
-- | 389.60 | 2,210.00 | -- | 140.31 |
|
Gross Profit
|
-- | 121.07 | 985.50 | -- | 156.35 |
|
Operating Expenses
|
1.65 | 140.27 | 860.90 | -- | 44.76 |
|
Operating Profit (EBIT)
|
-1.65 | -19.20 | 124.60 | -- | 111.59 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
0.28 | -1,314.15 | -112.40 | -- | 101.66 |
|
Provision for Tax
|
0.42 | 0.86 | 14.50 | -- | 25.34 |
|
Profit after Tax (Net Income)
|
-0.14 | -1,315.01 | -128.50 | -- | 75.72 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Qomolangma Acquisition Corp. Unit (QOMOU) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
4.34 | -820.18 | -1,045.40 | -- | 235.66 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
2.12 | 2,284.43 | 2,829.40 | -- | 177.50 |
|
Current Liabilities
|
2.91 | 134.56 | 3,208.70 | -- | 71.10 |
|
Total Liabilities
|
9.38 | 1,598.82 | 5,115.20 | -- | 1,216.11 |
Assets ($ Mln)
| Qomolangma Acquisition Corp. Unit (QOMOU) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
9.30 | 694.85 | 3,759.30 | -- | 142.80 |
|
Current Assets
|
0.08 | 903.96 | 1,355.90 | -- | 355.03 |
|
Total Assets
|
9.38 | 1,598.82 | 5,115.20 | -- | 1,216.11 |
|
Total Debt*
|
0.94 | 1,199.77 | 3,656.10 | -- | 152.34 |
|
Net Current Assets
|
-- | 769.40 | -1,852.80 | -- | -- |
Cashflow ($ Mln)
| Qomolangma Acquisition Corp. Unit (QOMOU) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-0.70 | 42.90 | -106.80 | -- | 243.51 |
|
Cash Flow from Investing Activities
|
46.96 | -95.19 | -35.40 | -- | -179.21 |
|
Cash from Financing Activities
|
-46.44 | 819.57 | 84.50 | -- | -13.84 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Qomolangma Acquisition Corp. Unit (QOMOU) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-2.89 | -405.74 | -4.96 | -- | 21.44 |
|
ROE (%)
|
-3.20 | 185.59 | 11.69 | -- | 37.44 |
|
ROA (%)
|
-1.48 | -113.81 | -2.52 | -- | 6.65 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | -257.50 | -4.02 | -- | 25.52 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Qomolangma Acquisition Corp. Unit (QOMOU) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 0.02 | 0.07 | -- | 0.13 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-0.07 | -433.50 | -37.43 | -- | -75.57 |
|
EPS Growth (%)
|
0.00 | -5.98 | -0.37 | -- | -0.77 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Qomolangma Acquisition Corp. Unit (QOMOU) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-203.46 | -2.64 | -17.07 | -- | 8.79 |
|
Price / Book Value
|
6.51 | -4.23 | -2.10 | -- | 2.82 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
105.51 | -3.29 | 3.20 | -- | 4.35 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Qomolangma Acquisition Corp. Unit (QOMOU) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.22 | -1.46 | -3.50 | -- | 0.65 |
|
Short term debt to equity ratio
|
0.22 | -0.03 | -1.75 | -- | 0.00 |
|
Current Ratio
|
0.03 | 6.72 | 0.42 | -- | 4.99 |
|
Quick Ratio
|
-- | -- | -- | -- | -- |
|
Interest Coverage
|
-- | -34.45 | 0.44 | -- | 9.47 |
Operating Efficiency Ratios
| Qomolangma Acquisition Corp. Unit (QOMOU) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 0.20 | 32.52 | -- | 104.49 |
|
Asset Turnover
|
-- | 0.44 | 0.63 | -- | 0.26 |
|
Receivable days
|
-- | 2.93 | 115.46 | -- | 428.91 |
|
Inventory Days
|
-- | -5.77 | -5.88 | -- | -1,881.69 |
|
Payable days
|
-- | 81.57 | 40.90 | -- | 318.72 |
|
Cash Conversion Cycle
|
-- | -84.42 | 68.68 | -- | -1,771.50 |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
